Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Cocks

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Pilot and Feasibility Studies|December 15, 2016
A randomised controlled feasibility trial of family and social network intervention for young people who misuse alcohol and drugs: study protocol (Y-SBNT)Judith Watson, Donna Back, Paul Toner, et al.
Annals of Hematology|May 1, 2012
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life GroupFabio Efficace, Massimo Breccia, Susanne Saussele, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
Eclinicalmedicine|June 16, 2025
The EORTC QLQ-F17 as a shortened version of the EORTC QLQ-C30 to assess self-reported functioning in cancer patients: investigating equivalence and psychometric properties in a randomized cross-over trialFlorian Zeman, Johannes M Giesinger, Tobias Pukrop, et al.
JNCI Cancer Spectrum|April 25, 2020
Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast CancerJammbe Z Musoro, Corneel Coens, Frederic Fiteni, et al.
JTO Clinical and Research Reports|June 26, 2025
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Silvia Novello, Pilar Garrido, et al.
Gynecologic Oncology|September 25, 2020
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancerJammbe Z Musoro, Corneel Coens, Elfriede Greimel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2023
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical TrialsBellinda L King-Kallimanis, Melanie Calvert, David Cella, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 12, 2017
International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemiaLonneke van de Poll-Franse, Simone Oerlemans, Anne Bredart, et al.
BMJ Open|January 13, 2018
Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocolZebedee Jammbe Musoro, Jean-Francois Hamel, Divine Ewane Ediebah, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Pilot and Feasibility Studies|December 15, 2016
A randomised controlled feasibility trial of family and social network intervention for young people who misuse alcohol and drugs: study protocol (Y-SBNT)Judith Watson, Donna Back, Paul Toner, et al.
Annals of Hematology|May 1, 2012
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life GroupFabio Efficace, Massimo Breccia, Susanne Saussele, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
Eclinicalmedicine|June 16, 2025
The EORTC QLQ-F17 as a shortened version of the EORTC QLQ-C30 to assess self-reported functioning in cancer patients: investigating equivalence and psychometric properties in a randomized cross-over trialFlorian Zeman, Johannes M Giesinger, Tobias Pukrop, et al.
JNCI Cancer Spectrum|April 25, 2020
Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast CancerJammbe Z Musoro, Corneel Coens, Frederic Fiteni, et al.
JTO Clinical and Research Reports|June 26, 2025
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Silvia Novello, Pilar Garrido, et al.
Gynecologic Oncology|September 25, 2020
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancerJammbe Z Musoro, Corneel Coens, Elfriede Greimel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2023
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical TrialsBellinda L King-Kallimanis, Melanie Calvert, David Cella, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 12, 2017
International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemiaLonneke van de Poll-Franse, Simone Oerlemans, Anne Bredart, et al.
BMJ Open|January 13, 2018
Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocolZebedee Jammbe Musoro, Jean-Francois Hamel, Divine Ewane Ediebah, et al.
Pageof 9